Ascendis Pharma A/S Statistics
Share Statistics
Ascendis Pharma A/S has 59.76M shares outstanding. The number of shares has increased by 1.33% in one year.
| Shares Outstanding | 59.76M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.3% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 59.25M |
| Failed to Deliver (FTD) Shares | 25 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 3.41M, so 5.7% of the outstanding shares have been sold short.
| Short Interest | 3.41M |
| Short % of Shares Out | 5.7% |
| Short % of Float | 5.75% |
| Short Ratio (days to cover) | 8.5 |
Valuation Ratios
The PE ratio is -13.32 and the forward PE ratio is -32.32.
| PE Ratio | -13.32 |
| Forward PE | -32.32 |
| PS Ratio | 24.05 |
| Forward PS | 15.1 |
| PB Ratio | -44.02 |
| P/FCF Ratio | -13.65 |
| PEG Ratio | n/a |
Enterprise Valuation
Ascendis Pharma A/S has an Enterprise Value (EV) of 6.67B.
| EV / Earnings | -13.85 |
| EV / Sales | 24.99 |
| EV / EBITDA | -16.21 |
| EV / EBIT | -14.63 |
| EV / FCF | -14.19 |
Financial Position
The company has a current ratio of 3.56, with a Debt / Equity ratio of -3.74.
| Current Ratio | 3.56 |
| Quick Ratio | 2.5 |
| Debt / Equity | -3.74 |
| Total Debt / Capitalization | 136.44 |
| Cash Flow / Debt | -0.86 |
| Interest Coverage | -10.34 |
Financial Efficiency
Return on equity (ROE) is 3.3% and return on capital (ROIC) is -92.78%.
| Return on Equity (ROE) | 3.3% |
| Return on Assets (ROA) | -0.58% |
| Return on Capital (ROIC) | -92.78% |
| Revenue Per Employee | 303.43K |
| Profits Per Employee | -547.72K |
| Employee Count | 879 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 0.21 |
Taxes
| Income Tax | 7.30M |
| Effective Tax Rate | -0.02 |
Stock Price Statistics
The stock price has increased by 7.67% in the last 52 weeks. The beta is 0.65, so Ascendis Pharma A/S's price volatility has been higher than the market average.
| Beta | 0.65 |
| 52-Week Price Change | 7.67% |
| 50-Day Moving Average | 129.49 |
| 200-Day Moving Average | 135.48 |
| Relative Strength Index (RSI) | 50.15 |
| Average Volume (20 Days) | 552.30K |
Income Statement
In the last 12 months, Ascendis Pharma A/S had revenue of $266.72M and earned -$481.45M in profits. Earnings per share was $-8.55.
| Revenue | 266.72M |
| Gross Profit | 222.32M |
| Operating Income | -455.54M |
| Net Income | -481.45M |
| EBITDA | -411.17M |
| EBIT | -455.54M |
| Earnings Per Share (EPS) | -8.55 |
Balance Sheet
The company has $392.16M in cash and $644.26M in debt, giving a net cash position of -$252.10M.
| Cash & Cash Equivalents | 392.16M |
| Total Debt | 644.26M |
| Net Cash | -252.10M |
| Retained Earnings | -2.28B |
| Total Assets | 1.09B |
| Working Capital | 135.28M |
Cash Flow
In the last 12 months, operating cash flow was -$467.36M and capital expenditures -$2.44M, giving a free cash flow of -$469.80M.
| Operating Cash Flow | -467.36M |
| Capital Expenditures | -2.44M |
| Free Cash Flow | -469.80M |
| FCF Per Share | -8.35 |
Margins
Gross margin is 83.36%, with operating and profit margins of -170.79% and -180.51%.
| Gross Margin | 83.36% |
| Operating Margin | -170.79% |
| Pretax Margin | -177.77% |
| Profit Margin | -180.51% |
| EBITDA Margin | -154.16% |
| EBIT Margin | -170.79% |
| FCF Margin | -176.14% |
Dividends & Yields
ASND does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -6.56% |
| FCF Yield | -6.04% |
Analyst Forecast
The average price target for ASND is $186, which is 42.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $186 |
| Price Target Difference | 42.8% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | 0.26 |
| Piotroski F-Score | 4 |